Core Technology

Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases


T cell response

BVAC activates T cells by presenting the tumor antigens on Major Histocompatibility Complex (MHC) class I and class II molecules.
The target tumor antigen forms a complex with either the MHC I or MHC II molecule: the MHC I complex activates CD8+ T cells and the MHC II complex activates CD4+ T cells.
The activated CD8+ T cells can proliferate, recognize the tumor antigen expressing tumor cells, and directly attack them.
Likewise, the activated CD4+ T cells can activate a variety of other immune cells which result in the killing of the tumor cells.

Scroll left and right to read.